Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Radiosurgery 8Docetaxel 4Cisplatin 4Carboplatin 4Magnetic Resonance Spectroscopy 3Filgrastim 3pembrolizumab 2Specimen Handling 2Radiotherapy 2Paclitaxel 2Nivolumab 2Mental Status and Dementia Tests 2Memantine 2Fluorodeoxyglucose F18 2Etoposide 2temsirolimus 1sargramostim 1sacituzumab govitecan 1regorafenib 1pentetreotide 1pazopanib 1molibresib 1etoposide phosphate 1etirinotecan pegol 1entinostat 1durvalumab 1cc-486 1budigalimab 1berzosertib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × berzosertib × CNS × Clear all
NCT02589522 2026-04-29

Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
15 enrolled 10 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡